Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| ENLV | Enlivex Therapeutics | 1.31% | 183.8M |
Enlivex Therapeutics Company Questions & Answers
Q
How do I buy Enlivex Therapeutics (ENLV) stock?
A
You can purchase shares of Enlivex Therapeutics (NASDAQ: ENLV) through any online brokerage.
Q
Who are Enlivex Therapeutics's (ENLV) main competitors?
A
There are no as such competitors for Enlivex Therapeutics.
Q
What is the target price for Enlivex Therapeutics?
A
The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by H.C. Wainwright on 2020-01-09. The analyst firm set a price target for 20.00 expecting ENLV to rise to within 12 months (a possible 99.20% upside). 0 analyst firms have reported ratings in the last year.
Q
How much is Enlivex Therapeutics (ENLV) stock ?
A
The stock price for Enlivex Therapeutics (NASDAQ: ENLV) is $10.04 last updated Fri May 07 2021 20:00:02 GMT+0000 (Coordinated Universal Time).
Q
When is the next Enlivex Therapeutics (ENLV) dividend?
A
There are no upcoming dividends for Enlivex Therapeutics.
Q
When is Enlivex Therapeutics (NASDAQ:ENLV) reporting earnings?
A
There are no earnings for Enlivex Therapeutics
Q
When is the upcoming split for ENLV?
A
There is no upcoming split for Enlivex Therapeutics.